EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both <i>in vitro</i> and <i>in vivo</i>

Abstract

We demonstrate that EGFR is a relevant immunotherapeutic target in TNBC, and EGFR CAR-T exhibits potent and specific antitumor activity against TNBC, suggesting the potential of this third-generation EGFR CAR-T as an immunotherapy tool to treat TNBC in the clinic.